Fundora-Hernández H, Torres-Lahera ML, García-Mirabal M, Díaz-Cabezas de Armada JV, Rodríguez-Ortega M

Language: Spanish
References: 17
Page: 135-143
PDF size: 298.54 Kb.

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 is the causative agent of COVID-19. In the week of March 21 to 27, 2021 an increase of 8% in cases was confirmed in Cuba. The Cuban Ministry of Public Health decided to approve the health intervention with the SOBERANA vaccine candidates to be administered to the staff working in health institutions. The objectives were to describe the vaccination coverage achieved with the SOBERANA heterologous scheme and the progression of the disease in the vaccinated subjects. This is a descriptive, prospective study. We perceived 884 subjects that fulfilled the criteria to be included. The subjects were followed up by the researchers of the sentinel site during the application of the scheme and 5 months after its conclusion. Adequate vaccination coverage was achieved for the heterologous scheme of three doses of SOBERANA. The most frequent comorbidities inside the group of workers who fell ill of COVID-19, 14 days after of completing the heterologous scheme were: high blood pressure, asthma, type 2 diabetes mellitus and ischemic heart disease. The bigger proportion of sick persons corresponded to those who worked in the high-risk red zone, followed by those who worked in the green zone and in the professional group, and lastly non-professional non-technical workers. Disease progression to severe and critical forms was not described in vaccinated workers. Symptoms and more frequent signs in the sick persons were fever, cough, asthenia and anorexia. Adequate vaccination coverage was achieved; the progression of the disease to severe or critical forms was aborted despite the high occupational exposure of the staff and chronic comorbidities.

REFERENCES

1. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: current state of the science. Immunity. 2020; 52(6): 910-41. doi: https://10.1016/j immuni.2020.05.002.

2. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med. 2020; 382(13): 1278-80. doi: https://10.1056/NEJMc2001899.

3. Centers for Disease Control and Prevention (CDC). ACIP Meeting, Overview of data to inform recommendations for booster doses of COVID-19 vaccines. Atlanta: CDC;2021. Disponible en: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/06-COVID-Oliver-508.pdf. (Consultado en línea: 15 de mayo de 2022).

4. Organización Panamericana de la Salud. Reporte de Situación COVID-19 Cuba No. 59 (29 de marzo de 2021). 2021. Washington DC: OPS. Disponible en: https://www.globalindexmedicus.net/es/. (Consultado en línea: 15 de mayo de 2022).

5. Asamblea Nacional del Poder Popular de Cuba. Ley no 41 de la Salud Pública Asamblea Nacional del Poder Popular. Gaceta Oficial de la República de Cuba No 61 Ordinaria (1983). Disponible en: https://siteal.iiep.unesco.org/sites/default/files/sit_accion_files/cuba_ley_ndeg_41_de_1983_ley_de_salud_publica.pdf. (Consultado en línea: 15 de mayo de 2022).

6. López Ambrón L, Egues Torres L, Pérez Carreras A, Galindo Santana B, Galindo Sardiña M, Resik Aguirre S, et al. Experiencia cubana en inmunización, 1962-2016. Rev Panam Salud Publica 2018; 42: e34. doi: https://10.26633/RPSP.2018.34.

7. Castillo-Santana E, Jesús-Arámboles Y, Catoia-Varela M, Bautista-Branagan C, Lara-Reyes EM, Dias-da-Costa M. Barreras para la inmunización en República Dominicana y COVID-19. Vaccimonitor.2021;30(3):96-104. Disponible en: https://vaccimonitor.finlay.edu.cu/index.php/vaccimonitor/article/view/274. (Consultado en línea: 15 de mayo de 2022).

8. Pereira-Victorio C, Saldivar-Tapia TL, Valladares-Garrido MJ. Coberturas de vacunación en tiempos de COVID-19: Un análisis desde la epidemiología social en la región del Cusco. Rev Cuerpo Med HNAAA.2020;13(2):167-74. doi:https://10.35434/rcmhnaaa.2020.132.668.

9. ourworlindata.org. COVID-19 vaccinations, cases, excess mortality, and much more. Oxford: Our Worl in Data; c2022-15. Disponible en: https://ourworlindata.org. (Consultado en línea: 15 de mayo de 2022).

10. Moraga Llop FA, Fernández-Prada M, Grande-Tejeda AM, Martínez-Alcorta LI, Moreno-Pérez D, Pérez-Martín JJ. Vacunas. 20020; 21(2):129-35. doi:https:// 10.1016/j.vacun.2020.07.001.

11. Giralt-Herrera A, Rojas-Velázquez J, Leiva-Enríquez J. Relación entre COVID-19 e hipertensión arterial. Rev Haban Cienc Med. 2020; 19(2): 1-11. Disponible en: http://www.revhabanera.sld.cu. (Consultado en línea: 15 de mayo de 2022).

12. Wang X, Zhang H, Du H, Ma R, Nan Y, Zhang T. Risk Factors for COVID-19 in Patients with Hypertension. Can J Infect Dis Med Microbiol. 2021; 2021:5515941. doi: https://10.1155/2021/5515941.

13. González R, Acosta F, Oliva E, Rodríguez S, Cabeza I. Diabetes, hiperglucemia y evolución de pacientes con la COVID-19. Rev Cuba Med Mil. 2021; 50(2): e910. Disponible en: http://www.revmedmilitar.sld.cu. (Consultado en línea: 15 de mayo de 2022).

14. Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 y diabetes mellitus: una relación bidireccional. Clin Investig Arterioscler. 2021;33(3):151-7. doi: https://10.1016/j.arteri.2020.10.001.

15. Catalá Ruiz P, Amat Santos I, Marcos M, Cabezón Villalba G, López Otero D, Aparisi Sanz A, et al. Cardiopatía isquémica y COVID-19. Rev Esp Cardiol. 2020; 73(Supl 1): 788. Disponible en: https://www.revespcardiol.org/es-congresos-sec-2020-el-e-congreso-110-sesion-sesion-6012-cardiopatia-isquemica-y-covid-19-71989. (Consultado en línea: 15 de mayo de 2022).

16. Nordstrom P, Ballin A, Nordstrom A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022; 399(10327): 814-23. doi: https://10.1016/S0140-6736(22)00089-7.

17. ZOE COVID Study. COVID Symptom Study App. Londres: School Communities Programme; 2021. Disponible en: https://www.klc.ac.uk. (Consultado en línea: 15 de mayo de 2022).